Posterior Extra-fascial RARP in Intermediate or High Risk Prostate Cancer
Launched by NING XU · May 23, 2024
Trial Information
Current as of February 19, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at two different surgical techniques used in a procedure called robot-assisted radical prostatectomy (RARP) for men with intermediate to high-risk prostate cancer. The goal is to see which technique is safer and more effective, helping doctors provide the best treatment options for patients facing this type of cancer. The study will compare the outcomes of patients using a posterior approach versus an anterior approach during surgery.
To participate in this trial, men aged 65 to 74 with intermediate or high-risk prostate cancer may be eligible, provided they have a prostate volume of less than 80 ml and a life expectancy of more than 10 years. Participants need to give their consent and must be assessed to ensure they can safely undergo the surgery. Throughout the trial, participants will receive close monitoring to evaluate their recovery and overall health outcomes. This study aims to provide valuable insights that could help improve surgical treatment choices for prostate cancer in the future.
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • 1. intermediate- and high-risk prostate cancer patients assessed by comprehensive clinical evaluation;
- • 2. prostate volume \<80 ml;
- • 3. life expectancy of patients \>10 years;
- • 4. patients sign the "informed consent";
- • 5. Routine preoperative examination has been improved (chest CT, electrocardiogram, and color Doppler echocardiography), and there is no serious basic disease. After clinical evaluation, it can tolerance robot-assisted radical prostatectomy (RARP).
- Exclusion Criteria:
- • 1. life expectancy \<10 years;
- • 2. comorbidities with other malignancies;
- • 3. uncorrected coagulation dysfunctions;
- • 4. patients with severe underlying diseases such as severe pulmonary insufficiency who could not tolerate the surgery;
- • 5. patients or family members who did not accept radical prostatectomy.
Trial Officials
Xue-Yi Xue
Study Director
the First Affiliated Hospital, Fujian Medical University
About Ning Xu
Ning Xu is a dedicated clinical trial sponsor focused on advancing medical research and innovation through rigorous and ethical clinical studies. With a commitment to improving patient outcomes, Ning Xu leverages a robust network of partnerships with healthcare professionals and research institutions to design and implement trials that adhere to the highest standards of scientific integrity and regulatory compliance. The organization emphasizes transparency, collaboration, and patient safety, striving to bring new therapies to market that address unmet medical needs and enhance the quality of care across diverse populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Fuzhou, Fujian, China
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0